Which medication should be increased for a patient with bipolar disorder on Auvelity (dextromethorphan/brasofensine), sertraline 25mg, and lamotrigine 25mg with persistent depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Persistent Depression in Bipolar Disorder

Lamotrigine should be increased first for this patient with bipolar disorder experiencing persistent depression despite current medication regimen. 1

Rationale for Medication Selection

The patient is currently on three medications:

  • Auvelity (dextromethorphan/bupropion) once daily (unable to tolerate twice daily)
  • Sertraline 25 mg
  • Lamotrigine 25 mg

When evaluating which medication to increase for persistent depression in bipolar disorder:

Lamotrigine (First Choice)

  • Lamotrigine is a first-line treatment for bipolar depression as recommended by the American Psychiatric Association 1
  • It has demonstrated significant antidepressant efficacy in bipolar depression without increasing the risk of mania or mood destabilization 2, 3
  • The current dose of 25 mg is significantly below therapeutic levels
  • Studies show efficacy at doses of 50-200 mg/day for bipolar depression 2
  • Lamotrigine is particularly effective in preventing depressive episodes, which dominate the clinical picture of bipolar disorder 4

Dosing Considerations

  • Lamotrigine requires slow titration to minimize risk of serious rash
  • Recommended titration:
    • Current: 25 mg daily
    • Week 1-2: Increase to 50 mg daily
    • Week 3-4: Increase to 100 mg daily
    • Further increases based on response (therapeutic range typically 100-200 mg daily)

Alternative Options (Less Preferred)

Sertraline

  • Current dose (25 mg) is subtherapeutic for depression
  • However, antidepressants in bipolar disorder carry risk of:
    • Triggering manic episodes
    • Causing rapid cycling
    • Mood destabilization 1
  • If increasing sertraline is considered, careful monitoring for signs of mania is essential

Auvelity

  • Patient already demonstrated intolerance to the standard twice-daily dosing
  • Limited evidence for its use specifically in bipolar depression
  • Attempting to increase may lead to recurrence of intolerance issues

Monitoring Recommendations

When increasing lamotrigine:

  • Monitor for rash (especially during titration)
  • Assess mood symptoms weekly during dose adjustments
  • Watch for signs of mood switching or destabilization
  • Evaluate overall efficacy for depression symptoms

Important Considerations

  • Lamotrigine has a more favorable side effect profile compared to many mood stabilizers 4
  • Slow titration is essential to minimize risk of serious skin reactions
  • The patient's anxiety has improved on current regimen, suggesting partial response
  • The goal is to address persistent depression while maintaining mood stability

Potential Pitfalls

  • Titrating lamotrigine too quickly increases risk of serious rash
  • Increasing sertraline could potentially trigger manic symptoms
  • Attempting higher doses of Auvelity may lead to intolerance issues again
  • Inadequate treatment of bipolar depression increases suicide risk 1

By prioritizing lamotrigine dose optimization, you're following evidence-based guidelines for bipolar depression management while minimizing risks of mood destabilization or medication intolerance.

References

Guideline

Neurological Effects of Medications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Lamotrigine in the treatment of bipolar depression.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1999

Research

Lamotrigine: A Safe and Effective Mood Stabilizer for Bipolar Disorder in Reproductive-Age Adults.

Medical science monitor : international medical journal of experimental and clinical research, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.